jzl-184 has been researched along with Neuroblastoma* in 1 studies
1 other study(ies) available for jzl-184 and Neuroblastoma
| Article | Year |
|---|---|
Dual inhibition of MAGL and type II topoisomerase by N-phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth.
The endocannabinoid system is implicated in numerous physiopathological processes while more and more pieces of evidence wave the link between this complex machinery and cancer related phenomenon. In these lines, we confirmed the effects of 2-arachidonoylglycerol (2-AG), the main endocannabinoid, on neuroblastoma cells proliferation in vitro, and proved that some N-phenylmaleimide compounds that were previously shown as MAGL inhibitors can also inhibit type 2 topoisomerase. We also shed light on their antiproliferative effects on a neuroblastoma cell line. In order to establish a link between MAGL inhibition, topoisomerase inhibition and the effects on N1E-115 cells, we tested combinations of maleimides or known endocannabinoid metabolism inhibitors and 2-AG, the major MAGL substrate, on N1E-115 cells. However, none of the inhibitors tested, except the carbamate CAY10499, managed to increase 2-AG's effects. Even the MAGL reference inhibitor JZL184 failed to induce a stronger inhibition of proliferation. Topics: Antineoplastic Agents; Arachidonic Acids; Benzodioxoles; Cannabinoid Receptor Modulators; Carbamates; Cell Proliferation; DNA Topoisomerases, Type II; Endocannabinoids; Etoposide; Glycerides; Humans; Maleimides; Monoacylglycerol Lipases; Neuroblastoma; Oxadiazoles; Piperidines; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2012 |